Breast Cancer Liquid Biopsy Market Size, Share, Trends, Growth Outlook

Breast Cancer Liquid Biopsy Market is estimated to increase at a Compounded Annual Growth Rate of 21.6% CAGR over the forecast period from 2024 to 2030

The Breast Cancer Liquid Biopsy Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Circulating Biomarkers (Circulating Tumor Cells (CTCs), Circulating Cell-free DNA (cfDNA), Extracellular Vesicles, Others), By Application (Early Detection/Screening, Diagnosis, Treatment Selection, Monitoring).

An Introduction to Breast Cancer Liquid Biopsy Market in 2024

Breast cancer liquid biopsy is a non-invasive diagnostic test used to detect circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other biomarkers in blood samples from patients with breast cancer. In 2024, the field of breast cancer liquid biopsy continues to advance with innovations in technology, biomarker discovery, and assay sensitivity aimed at improving early detection, treatment monitoring, and personalized therapy selection. These tests offer several advantages over traditional tissue biopsies, including real-time monitoring of disease progression, assessment of treatment response, and identification of actionable mutations for targeted therapy. Moreover, with the development of multiplexed assays and next-generation sequencing platforms, liquid biopsy tests can provide comprehensive genomic profiling, guiding treatment decisions and predicting treatment resistance. By offering a minimally invasive and informative approach to breast cancer management, liquid biopsy tests empower clinicians to deliver timely and targeted interventions, optimize treatment outcomes, and improve the overall survival and quality of life for patients with breast cancer.

Market Trend: Advancements in Liquid Biopsy Technologies

A significant trend in the breast cancer liquid biopsy market is the rapid advancements in liquid biopsy technologies for early detection, monitoring, and personalized treatment of breast cancer. Liquid biopsy techniques, such as circulating tumor DNA (ctDNA) analysis, circulating tumor cells (CTCs) enumeration, and exosome profiling, offer minimally invasive methods for detecting tumor-derived biomarkers in blood samples. These technologies enable clinicians to assess tumor heterogeneity, monitor treatment response, detect minimal residual disease, and identify actionable mutations or therapeutic targets in real-time. With ongoing research and development efforts aimed at improving assay sensitivity, specificity, and scalability, liquid biopsy technologies are poised to revolutionize the management of breast cancer by providing non-invasive, dynamic insights into tumor biology and treatment response.

Market Driver: Need for Non-Invasive and Personalized Diagnostic Solutions

The primary driver fueling the growth of the breast cancer liquid biopsy market is the increasing need for non-invasive and personalized diagnostic solutions that complement traditional tissue biopsies and imaging modalities. Tissue biopsies, while considered the gold standard for diagnosing breast cancer, can be invasive, costly, and subject to sampling errors. Additionally, they may not capture the molecular heterogeneity of tumors or provide real-time information on treatment response. Liquid biopsy offers a less invasive alternative for obtaining comprehensive molecular profiles of breast tumors through serial blood draws, enabling clinicians to tailor treatment strategies, monitor disease progression, and make informed clinical decisions. With the growing emphasis on precision medicine and targeted therapies in breast cancer management, liquid biopsy technologies play a crucial role in guiding treatment selection, predicting treatment response, and optimizing patient outcomes.

Market Opportunity: Integration with Multimodal Diagnostic Platforms

A potential opportunity for the breast cancer liquid biopsy market lies in the integration of liquid biopsy technologies with multimodal diagnostic platforms for comprehensive disease characterization and patient management. While liquid biopsy provides valuable insights into tumor biology and treatment response, it is often used in conjunction with other diagnostic modalities, such as imaging, histopathology, and genomic profiling, to achieve a more comprehensive understanding of the disease. Integrating liquid biopsy data with multimodal diagnostic platforms enables clinicians to correlate molecular findings with clinical and radiological parameters, facilitating more accurate disease staging, treatment planning, and prognostic assessment. Furthermore, the integration of liquid biopsy technologies with artificial intelligence (AI) algorithms and predictive analytics enhances data interpretation, biomarker discovery, and patient stratification, enabling more personalized and effective therapeutic interventions. By developing integrated diagnostic platforms that combine liquid biopsy with complementary technologies, manufacturers can offer comprehensive solutions that support the continuum of breast cancer care, from early detection and diagnosis to treatment monitoring and disease surveillance.

Breast Cancer Liquid Biopsy Market Share Analysis: Extracellular Vesicles is the fastest growing segment over the forecast period to 2030

Extracellular vesicles (EVs) represent a swiftly growing segment within the breast cancer liquid biopsy market, primarily due to their unique characteristics and diverse potential applications. EVs, which include exosomes and microvesicles, are secreted by various cell types, including cancer cells, and contain a cargo of proteins, nucleic acids, and lipids reflective of their cell of origin. This makes them promising targets for liquid biopsy-based cancer diagnostics and monitoring. EVs offer advantages such as stability in bodily fluids, protection of their cargo from degradation, and the ability to cross biological barriers, allowing for non-invasive sample collection and analysis. Moreover, EVs hold immense potential in early cancer detection, as they can carry cancer-specific biomarkers indicative of disease onset even before symptoms manifest. As research continues to unveil the diagnostic and prognostic value of EVs in breast cancer, coupled with advancements in isolation and detection techniques, the market for EV-based liquid biopsy assays is poised for significant growth in the coming years.

Breast Cancer Liquid Biopsy Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossBiocept Inc, Epic Sciences Inc, F. Hoffmann-La Roche Ltd, Fluxion Biosciences Inc, Myriad Genetics Inc, NeoGenomics Laboratories Inc, QIAGEN N.V., Sysmex Corp, The Menarini Group, Thermo Fisher Scientific Inc

Breast Cancer Liquid Biopsy Market Segmentation

By Circulating Biomarkers
Circulating Tumor Cells (CTCs)
Circulating Cell-free DNA (cfDNA)
Extracellular Vesicles
Others
By Application
Early Detection/Screening
Diagnosis
Treatment Selection
Monitoring
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Breast Cancer Liquid Biopsy Market Companies

Biocept Inc
Epic Sciences Inc
F. Hoffmann-La Roche Ltd
Fluxion Biosciences Inc
Myriad Genetics Inc
NeoGenomics Laboratories Inc
QIAGEN N.V.
Sysmex Corp
The Menarini Group
Thermo Fisher Scientific Inc

Reasons to Buy the Breast Cancer Liquid Biopsy Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Breast Cancer Liquid Biopsy Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Breast Cancer Liquid Biopsy Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Breast Cancer Liquid Biopsy Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Breast Cancer Liquid Biopsy Market Size Outlook, $ Million, 2021 to 2030
3.2 Breast Cancer Liquid Biopsy Market Outlook by Type, $ Million, 2021 to 2030
3.3 Breast Cancer Liquid Biopsy Market Outlook by Product, $ Million, 2021 to 2030
3.4 Breast Cancer Liquid Biopsy Market Outlook by Application, $ Million, 2021 to 2030
3.5 Breast Cancer Liquid Biopsy Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Breast Cancer Liquid Biopsy Industry
4.2 Key Market Trends in Breast Cancer Liquid Biopsy Industry
4.3 Potential Opportunities in Breast Cancer Liquid Biopsy Industry
4.4 Key Challenges in Breast Cancer Liquid Biopsy Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Breast Cancer Liquid Biopsy Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Breast Cancer Liquid Biopsy Market Outlook by Segments
7.1 Breast Cancer Liquid Biopsy Market Outlook by Segments, $ Million, 2021- 2030
By Circulating Biomarkers
Circulating Tumor Cells (CTCs)
Circulating Cell-free DNA (cfDNA)
Extracellular Vesicles
Others
By Application
Early Detection/Screening
Diagnosis
Treatment Selection
Monitoring

8 North America Breast Cancer Liquid Biopsy Market Analysis and Outlook To 2030
8.1 Introduction to North America Breast Cancer Liquid Biopsy Markets in 2024
8.2 North America Breast Cancer Liquid Biopsy Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Breast Cancer Liquid Biopsy Market size Outlook by Segments, 2021-2030
By Circulating Biomarkers
Circulating Tumor Cells (CTCs)
Circulating Cell-free DNA (cfDNA)
Extracellular Vesicles
Others
By Application
Early Detection/Screening
Diagnosis
Treatment Selection
Monitoring

9 Europe Breast Cancer Liquid Biopsy Market Analysis and Outlook To 2030
9.1 Introduction to Europe Breast Cancer Liquid Biopsy Markets in 2024
9.2 Europe Breast Cancer Liquid Biopsy Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Breast Cancer Liquid Biopsy Market Size Outlook by Segments, 2021-2030
By Circulating Biomarkers
Circulating Tumor Cells (CTCs)
Circulating Cell-free DNA (cfDNA)
Extracellular Vesicles
Others
By Application
Early Detection/Screening
Diagnosis
Treatment Selection
Monitoring

10 Asia Pacific Breast Cancer Liquid Biopsy Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Breast Cancer Liquid Biopsy Markets in 2024
10.2 Asia Pacific Breast Cancer Liquid Biopsy Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Breast Cancer Liquid Biopsy Market size Outlook by Segments, 2021-2030
By Circulating Biomarkers
Circulating Tumor Cells (CTCs)
Circulating Cell-free DNA (cfDNA)
Extracellular Vesicles
Others
By Application
Early Detection/Screening
Diagnosis
Treatment Selection
Monitoring

11 South America Breast Cancer Liquid Biopsy Market Analysis and Outlook To 2030
11.1 Introduction to South America Breast Cancer Liquid Biopsy Markets in 2024
11.2 South America Breast Cancer Liquid Biopsy Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Breast Cancer Liquid Biopsy Market size Outlook by Segments, 2021-2030
By Circulating Biomarkers
Circulating Tumor Cells (CTCs)
Circulating Cell-free DNA (cfDNA)
Extracellular Vesicles
Others
By Application
Early Detection/Screening
Diagnosis
Treatment Selection
Monitoring
12 Middle East and Africa Breast Cancer Liquid Biopsy Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Breast Cancer Liquid Biopsy Markets in 2024
12.2 Middle East and Africa Breast Cancer Liquid Biopsy Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Breast Cancer Liquid Biopsy Market size Outlook by Segments, 2021-2030
By Circulating Biomarkers
Circulating Tumor Cells (CTCs)
Circulating Cell-free DNA (cfDNA)
Extracellular Vesicles
Others
By Application
Early Detection/Screening
Diagnosis
Treatment Selection
Monitoring

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Biocept Inc
Epic Sciences Inc
F. Hoffmann-La Roche Ltd
Fluxion Biosciences Inc
Myriad Genetics Inc
NeoGenomics Laboratories Inc
QIAGEN N.V.
Sysmex Corp
The Menarini Group
Thermo Fisher Scientific Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Circulating Biomarkers
Circulating Tumor Cells (CTCs)
Circulating Cell-free DNA (cfDNA)
Extracellular Vesicles
Others
By Application
Early Detection/Screening
Diagnosis
Treatment Selection
Monitoring
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)